4//SEC Filing
William Arsani 4
Accession 0001209191-21-024224
CIK 0001807120other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 6:12 PM ET
Size
14.3 KB
Accession
0001209191-21-024224
Insider Transaction Report
Form 4
William Arsani
Director
Transactions
- Conversion
Series B Preferred Stock
2021-03-30−1,984,733→ 0 total(indirect: By Logos Opportunities Fund II, L.P.)→ Common Stock (1,217,627 underlying) - Purchase
Common Stock
2021-03-30$20.00/sh+700,000$14,000,000→ 2,732,501 total(indirect: By Logos Global Master Fund LP) - Conversion
Common Stock
2021-03-30+1,217,627→ 1,217,627 total(indirect: By Logos Opportunities Fund II, L.P.) - Conversion
Common Stock
2021-03-30+814,874→ 2,032,501 total(indirect: By Logos SPV I LP) - Conversion
Series B Preferred Stock
2021-03-30−1,328,245→ 0 total(indirect: By Logos SPV 1 LP)→ Common Stock (814,874 underlying)
Footnotes (3)
- [F1]All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
- [F2]The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F3]Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Design Therapeutics, Inc.
CIK 0001807120
Entity typeother
Related Parties
1- filerCIK 0001848372
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 6:12 PM ET
- Size
- 14.3 KB